CGBIO (CEO Hyun Seung Yu), a leading regenerative medicine company, announced it has significantly strengthened its position in the global aesthetic and plastic surgery market through its participation in IMCAS WORLD CONGRESS 2025, held in Paris, France.
IMCAS (International Master Course on Aging Science) is the world’s largest academic congress in the aesthetic and plastic surgery field. This year’s event drew 20,121 medical professionals from 136 countries, with 1,061 speakers and 374 exhibitors, setting new records for scale and participation.
At the event, CGBIO operated an exclusive booth, spotlighting its flagship aesthetic products—including the Facetem, AiLEENE, and GISELLELIGNE fillers, as well as the LUXX polydioxanone (PDO) suture line. The company focused on strengthening global brand visibility and forging high-impact international partnerships.
CGBIO signed a three-year, $11.4 million (KRW 15 billion) exclusive supply agreement for LUXX sutures with Cimed, a major OTC pharmaceutical firm in Brazil. Additional confirmed on-site orders from Brazil, Argentina, Colombia, and Peru totaled $3 million (KRW 4 billion).
The company also inked a $9.1 million (KRW 12 billion), three-year agreement to supply Facetem and GISELLELIGNE fillers to distributors in Greece, Iraq, and Israel. Furthermore, CGBIO secured $13.2 million (KRW 17.3 billion) in contracts across 18 countries, including Spain, the UK, Italy, Portugal, Greece, and Saudi Arabia, for its full range of filler products.
As part of its global education efforts, CGBIO hosted a featured lecture by Dr. Renato Pazzini, a renowned Brazilian dermatologist, who introduced cutting-edge full-body regenerative treatment techniques using calcium hydroxyapatite (CaHa). The session was presented under the IMCAS Open Stage – Industry Sponsored Lectures.
As part of the “Meet the Master” program, Dr. Koriakina Olga from Portugal introduced non-surgical facial rejuvenation techniques utilizing CaHa-based fillers, and shared methods for correcting perioral wrinkles using AiLEENE, a hyaluronic acid (HA) filler. Dr. Erivan Perez Montilla, also from Portugal, presented advanced lifting techniques that combine the Facetem filler with LUXX PDO sutures for optimized outcomes. Meanwhile, Dr. Mark McKelvie from the UK showcased emerging treatment protocols and diverse clinical applications of GISELLELIGNE fillers, offering insights into their expanding role in aesthetic medicine.
“IMCAS 2025 was a powerful platform to reaffirm the global competitiveness of our innovative products,” said Hyun Seung Yu, CEO of CGBIO. “We are committed to strengthening our global presence through continuous R&D and by expanding our international network. With differentiated technologies and strategic market entry, we aim to lead the future of aesthetic and regenerative medicine.”
Looking ahead, CGBIO plans to expand its distributor network across Europe, the Middle East, and the CIS (Commonwealth of Independent States). The company will also intensify its focus on product innovation and market-driven strategies to align with emerging global trends in aesthetic medicine.
▲ [PHOTO2] CGBIO IMCAS
▲ [PHOTO3] CGBIO IMCAS
